IL161685A0 - An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof - Google Patents

An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Info

Publication number
IL161685A0
IL161685A0 IL16168502A IL16168502A IL161685A0 IL 161685 A0 IL161685 A0 IL 161685A0 IL 16168502 A IL16168502 A IL 16168502A IL 16168502 A IL16168502 A IL 16168502A IL 161685 A0 IL161685 A0 IL 161685A0
Authority
IL
Israel
Prior art keywords
necrosis factor
tumor necrosis
ligand receptor
inducing ligand
related apoptosis
Prior art date
Application number
IL16168502A
Other languages
English (en)
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of IL161685A0 publication Critical patent/IL161685A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
IL16168502A 2001-11-01 2002-11-01 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof IL161685A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34640201P 2001-11-01 2001-11-01
PCT/US2002/035333 WO2003037913A2 (en) 2001-11-01 2002-11-01 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Publications (1)

Publication Number Publication Date
IL161685A0 true IL161685A0 (en) 2004-09-27

Family

ID=23359208

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16168502A IL161685A0 (en) 2001-11-01 2002-11-01 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
IL161685A IL161685A (en) 2001-11-01 2004-04-29 Selective antibody for ligand-receptor binding that causes cell death by 4DR tumor necrosis factor and its uses
IL196082A IL196082A (en) 2001-11-01 2008-12-18 Nucleotide acid containing a nucleotide sequence that encodes a chain of selective antibody for ligand-receptor binding that affects cell death by TNF (tumor necrosis factor) 4DR and related uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL161685A IL161685A (en) 2001-11-01 2004-04-29 Selective antibody for ligand-receptor binding that causes cell death by 4DR tumor necrosis factor and its uses
IL196082A IL196082A (en) 2001-11-01 2008-12-18 Nucleotide acid containing a nucleotide sequence that encodes a chain of selective antibody for ligand-receptor binding that affects cell death by TNF (tumor necrosis factor) 4DR and related uses

Country Status (19)

Country Link
EP (2) EP1506011B1 (ja)
JP (1) JP4371814B2 (ja)
KR (1) KR101004098B1 (ja)
CN (1) CN100482276C (ja)
AU (1) AU2002350121B2 (ja)
BR (1) BRPI0213844B8 (ja)
CA (1) CA2465040C (ja)
CO (1) CO5580833A2 (ja)
ES (1) ES2357225T3 (ja)
HU (1) HUP0700077A3 (ja)
IL (3) IL161685A0 (ja)
MX (1) MXPA04004185A (ja)
NO (1) NO338458B1 (ja)
NZ (1) NZ532591A (ja)
PL (1) PL211755B1 (ja)
RO (1) RO123115B1 (ja)
RU (1) RU2313537C2 (ja)
WO (1) WO2003037913A2 (ja)
ZA (2) ZA200403116B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
AU2002366430B2 (en) 2001-07-03 2008-09-18 Genentech, Inc. Human DR4 antibodies and uses thereof
US20040089839A1 (en) 2002-10-25 2004-05-13 Honeywell International, Inc. Fluorinated alkene refrigerant compositions
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
BR0316737A (pt) * 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
ATE508205T1 (de) 2004-08-06 2011-05-15 Genentech Inc Tests und verfahren unter verwendung von biomarkern
WO2006017859A2 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
CN100427505C (zh) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
ATE540318T1 (de) 2005-08-16 2012-01-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
BRPI0706530A2 (pt) * 2006-01-13 2011-03-29 Irm Llc métodos e composições para tratamento de doenças alérgicas
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
KR20090093959A (ko) 2006-10-23 2009-09-02 더 유에이비 리서치 파운데이션 항암제에 대한 감수성을 나타내는 암에 대한 생체마커 및 이의 용도
JPWO2009020094A1 (ja) * 2007-08-09 2010-11-04 第一三共株式会社 疎水性分子で修飾した抗体
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
KR101814852B1 (ko) 2010-10-29 2018-01-04 다이이찌 산쿄 가부시키가이샤 신규 항 dr5 항체
JP6132833B2 (ja) 2011-04-29 2017-05-24 ザ ペン ステイト リサーチ ファンデーション 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
JP6602875B2 (ja) 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Ｄｒ５結合ドメインを含む多価分子
BR112018070452A2 (pt) * 2016-04-05 2019-02-05 Baliopharm Ag um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
DK1053256T3 (da) * 1998-01-26 2011-10-03 Genentech Inc Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
AU4984300A (en) * 1999-05-06 2000-11-21 Vishva M Dixit Death domain containing receptor 4
AU781952B2 (en) * 1999-05-28 2005-06-23 Genentech Inc. DR4 antibodies and uses thereof
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
WO2003037913A3 (en) 2004-11-18
AU2002350121B2 (en) 2007-09-06
JP4371814B2 (ja) 2009-11-25
EP2287285A2 (en) 2011-02-23
EP1506011A4 (en) 2006-07-12
RO123115B1 (ro) 2010-11-30
MXPA04004185A (es) 2005-05-16
NO20042269L (no) 2004-06-30
RU2313537C2 (ru) 2007-12-27
PL373531A1 (en) 2005-09-05
CO5580833A2 (es) 2005-11-30
PL211755B1 (pl) 2012-06-29
CN100482276C (zh) 2009-04-29
WO2003037913A2 (en) 2003-05-08
HUP0700077A2 (en) 2007-05-02
ES2357225T3 (es) 2011-04-20
KR20040070349A (ko) 2004-08-07
RU2004116475A (ru) 2005-04-20
ZA200507050B (en) 2010-03-31
EP1506011B1 (en) 2015-08-19
CA2465040C (en) 2013-12-10
NO338458B1 (no) 2016-08-15
NZ532591A (en) 2008-04-30
CN1655814A (zh) 2005-08-17
BR0213844A (pt) 2006-05-23
JP2005509414A (ja) 2005-04-14
CA2465040A1 (en) 2003-05-08
BRPI0213844B1 (pt) 2018-12-26
HUP0700077A3 (en) 2012-09-28
BRPI0213844B8 (pt) 2021-05-25
KR101004098B1 (ko) 2011-01-13
EP2287285A3 (en) 2012-05-02
IL196082A (en) 2011-04-28
EP1506011A2 (en) 2005-02-16
IL161685A (en) 2011-03-31
ZA200403116B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
ZA200507050B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HUP0400951A3 (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HUP0600602A2 (en) Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
EP2363404B8 (en) PSMA antibodies
EP1396500A4 (en) ANTI-TRAIL-R ANTIBODIES
EP1790663A4 (en) MONOCLONAL ANTIBODY (AD5-10) AGAINST THE TUMOR NEKROSIS FACTOR RELATED APOPTOSIS-INDUCING LIGAND RESPECTOR DR5, METHOD OF MANUFACTURE AND APPLICATIONS THEREOF
IL161439A0 (en) Cannabinoid receptor ligands
PL364624A1 (en) Cannabinoid receptor ligands
AU2001271714A1 (en) B7-like polynucleotides, polypeptides, and antibodies
EP1461082A4 (en) ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
EP1383801A4 (en) ANTIBODIES AGAINST CANCER
AU8066701A (en) Capsaicin receptor ligands
IL156955A0 (en) Binding domain-immunoglobulin fusion proteins
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
IL161409A0 (en) Methods for ligand discovery
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
IL157031A0 (en) Thyroid receptor ligands
MXPA02012429A (es) Intercambiador de aniones monodispersados.
EP1411357A4 (en) CANCER DIAGNOSTICS
AU2002351469A8 (en) Acrp30-like polynucleotides, polypeptides, and antibodies
EP1454914A4 (en) TUMOR ANTIGEN
AU9389301A (en) Peptide ligands for prostate specific antigen
AU2002237421A1 (en) Nuclear hormone receptor ligand binding domains
EP1403283A4 (en) TUMOR ANTIGENS

Legal Events

Date Code Title Description
FF Patent granted